Has the German Pharma Industry valuation changed over the past few years?

Investors are optimistic on the German Pharmaceuticals industry, and appear confident in long term growth rates. The industry is trading at a PE ratio of 200x which is higher than its 3-year average PE of 130x. The industry is trading close to its 3-year average PS ratio of 1.3x.

Which industries have driven the changes within the German Healthcare industry?

There are no additional sub-industries under this industry.

German (DAX) Pharma Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Mon, 15 Jun 2026	€96.7b	€67.4b	€482.5m	22.9x	200.4x	1.4x
Wed, 13 May 2026	€90.0b	€67.9b	-€888,688,801.15	18.1x	-101.3x	1.3x
Fri, 10 Apr 2026	€91.1b	€67.9b	-€900,274,872.40	19.3x	-101.2x	1.3x
Sun, 08 Mar 2026	€86.4b	€67.9b	-€902,794,919.14	18.1x	-95.7x	1.3x
Tue, 03 Feb 2026	€102.1b	€68.3b	€2.9b	17.4x	35.6x	1.5x
Thu, 01 Jan 2026	€92.6b	€68.3b	€2.9b	18.1x	32.3x	1.4x
Sat, 29 Nov 2025	€83.6b	€68.5b	€2.9b	17.5x	29x	1.2x
Mon, 27 Oct 2025	€80.3b	€68.8b	-€439,053,836.05	19.2x	-183x	1.2x
Wed, 24 Sep 2025	€78.3b	€68.8b	-€438,204,667.66	17.9x	-178.7x	1.1x
Fri, 22 Aug 2025	€78.8b	€68.9b	-€409,703,873.07	17.5x	-192.3x	1.1x
Sun, 20 Jul 2025	€77.7b	€69.4b	-€283,071,598.00	17.4x	-274.5x	1.1x
Tue, 17 Jun 2025	€79.5b	€69.4b	-€206,268,848.00	18.1x	-385.3x	1.1x
Thu, 15 May 2025	€78.3b	€69.2b	-€237,208,637.00	18.9x	-330.2x	1.1x
Sat, 12 Apr 2025	€72.5b	€69.3b	€467.0m	17.7x	155.2x	1x
Mon, 10 Mar 2025	€84.5b	€69.2b	€436.0m	21.2x	193.7x	1.2x
Wed, 05 Feb 2025	€86.2b	€69.2b	€2.0b	22.7x	42.5x	1.2x
Fri, 03 Jan 2025	€82.9b	€69.2b	€2.0b	22.6x	41.2x	1.2x
Sun, 01 Dec 2024	€83.1b	€69.2b	€2.0b	21.4x	41x	1.2x
Tue, 29 Oct 2024	€95.6b	€69.4b	€1.6b	20.6x	61.3x	1.4x
Thu, 26 Sep 2024	€97.9b	€69.3b	€1.5b	23.6x	66.5x	1.4x
Sat, 24 Aug 2024	€104.4b	€69.3b	€1.5b	31.2x	71.6x	1.5x
Mon, 22 Jul 2024	€93.3b	€69.2b	-€303,627,757.00	28.9x	-307.4x	1.3x
Wed, 19 Jun 2024	€101.8b	€69.2b	-€328,028,608.00	21x	-310.3x	1.5x
Fri, 17 May 2024	€104.1b	€69.2b	-€312,802,180.00	21.7x	-332.7x	1.5x
Sun, 14 Apr 2024	€95.7b	€70.0b	-€34,208,180.00	20.8x	-2796.8x	1.4x
Tue, 12 Mar 2024	€97.1b	€70.0b	€6.5m	19.7x	14946.7x	1.4x
Thu, 08 Feb 2024	€95.9b	€70.6b	-€650,504,143.00	19.4x	-147.5x	1.4x
Sat, 06 Jan 2024	€99.2b	€70.6b	-€650,504,143.00	20x	-152.5x	1.4x
Mon, 04 Dec 2023	€102.3b	€70.6b	-€650,606,256.00	19x	-157.2x	1.4x
Wed, 01 Nov 2023	€104.3b	€72.1b	€4.7b	17x	22.3x	1.4x
Fri, 29 Sep 2023	€115.0b	€72.1b	€4.7b	22x	24.6x	1.6x
Sun, 27 Aug 2023	€122.1b	€72.1b	€4.7b	22.6x	26.2x	1.7x
Tue, 25 Jul 2023	€122.1b	€74.1b	€6.5b	18.9x	18.9x	1.6x
Thu, 22 Jun 2023	€118.7b	€74.1b	€6.4b	20.3x	18.5x	1.6x


DE Market	-0.16%
Healthcare	-0.42%
Pharma	-1.28%
Pharma	-1.28%

Company	Last Price	7D	1Y	Valuation
BAYN Bayer	€36.31	1.7% +€609.1m	31.7%	PS0.8x
DMP Dermapharm Holding	€47.95	2.0% +€47.1m	34.3%	PE16.5x
93M1 MPH Health Care	€27.10	3.4% +€3.9m	39.0%	PS2.3x

Announcement • 8h

Bayer Receives FDA Approval for Ambelvist for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity

Bayer had the U.S. Food and Drug Administration (FDA) approve AMBELVIST (gadoquatrane), a new, intravenous macrocyclic gadolinium (Gd)-based contrast agent (mGBCA) indicated for contrast-enhanced magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in the central nervous system (CNS) and non-CNS body regions in adult and pediatric patients, including term neonates. AMBELVIST is a next-generation mGBCA with a novel tetrameric structure and high relaxivity (a measure of signal enhancement). AMBELVIST becomes the lowest-dose mGBCA in the U.S. AMBELVIST has a recommended dose of 0.01 mmol/kg actual body weight (which delivers 0.04 mmol Gd/kg body weight), representing 60% less Gd compared to mGBCAs with a Gd content of 0.1 mmol Gd/kg body weight and 20% less Gd compared to gadopiclenol with a Gd content of 0.05 mmol Gd/kg body weight. Approval is supported by data from the Phase III QUANTI clinical studies, which demonstrated efficacy at a fraction of the dose compared to mGBCAs dosed at 0.1 mmol Gd/kg body weight. The FDA approval is based on the global pivotal Phase III QUANTI clinical studies, which evaluated the efficacy and safety of AMBELVIST in adult and pediatric patients, including term neonates, undergoing contrast-enhanced MRI. Key findings demonstrated increased lesion visualization with the combined pre-contrast and post-contrast MRI sets with the decreased Gd dose in AMBELVIST compared with only pre-contrast MRI images. Visualization scores and number of lesions identified per blinded independent reader for AMBELVIST dosed at 0.01 mmol/kg body weight (which delivers 0.04 mmol Gd/kg body weight) were similar to other tested mGBCAs with a Gd content of 0.1 mmol Gd/kg body weight in descriptive analyses. The safety and effectiveness of AMBELVIST for use with MRI to detect and visualize lesions with abnormal vascularity in the CNS (brain, spine and associated tissues) and the body (head and neck, thorax, abdomen, pelvis and musculoskeletal system) have been established in pediatric patients, including term neonates. Use of AMBELVIST in this age group is supported by evidence from adequate and well-controlled studies of AMBELVIST in adults, with additional pharmacokinetic and safety data from 93 pediatric patients aged 28 days to less than 18 years who received one 0.01 mmol/kg dose of AMBELVIST and underwent MRI of any body region. AMBELVIST is associated with a Boxed Warning regarding risks associated with intrathecal administration and nephrogenic systemic fibrosis and is contraindicated in patients with a history of severe hypersensitivity reactions to AMBELVIST. Additionally, there are Warnings and Precautions related to hypersensitivity reactions, gadolinium retention, acute kidney injury and interference with lesion visualization. AMBELVIST (gadoquatrane) is a gadolinium-based contrast agent indicated in adult and pediatric patients, including term neonates, for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in the central nervous system (brain, spine, and associated tissues) and the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system). Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. AMBELVIST is not approved for intrathecal use. GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of AMBELVIST in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle, and internal organs. The risk for NSF appears highest among patients with chronic, severe kidney disease (GFR < 30 mL/min/1.73 m2), or acute kidney injury. Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (for example, age > 60 years, hypertension, or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing. For patients at highest risk for NSF, do not exceed the recommended AMBELVIST dose and allow a sufficient period of time for elimination of the drug from the body prior to any re-administration. AMBELVIST is contraindicated in patients with a history of severe hypersensitivity reactions to AMBELVIST. Serious hypersensitivity reactions have occurred with GBCAs. Before AMBELVIST administration, assess all patients for any history of a reaction to contrast media, bronchial asthma, and/or allergic disorders. These patients may have an increased risk for a hypersensitivity reaction to AMBELVIST. Gadolinium is retained for months or years in several organs. Linear GBCAs cause more retention than macrocyclic GBCAs. At equivalent doses, retention varies among the linear agents. Retention is lowest and similar among the macrocyclic GBCAs. Consequences of gadolinium retention in the brain have not been established, but they have been established in the skin and other organs in patients with impaired renal function. While clinical consequences of gadolinium retention have not been established in patients with normal renal function, certain patients might be at higher risk. These include patients requiring multiple lifetime doses, pregnant and pediatric patients, and patients with inflammatory conditions. Consider the retention characteristics of the agent and minimize repetitive GBCA studies, when possible. In patients with chronic renal impairment, acute kidney injury sometimes requiring dialysis has been observed with the use of some GBCAs. Do not exceed the recommended dose; the risk of acute kidney injury may increase with higher than recommended doses. As with other GBCAs, AMBELVIST may obscure certain lesions that are visible on non-contrast MRI. When available, non-contrast MRI images should be reviewed during the interpretation of AMBELVIST MRI scans. The most frequently observed adverse reactions (incidence = 0.2%) were dizziness, headache, injection site reactions, nausea, vomiting, feeling hot, paresthesia, and pruritus.

German (DAX) Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Bayer Receives FDA Approval for Ambelvist for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity

Merck Announces Management Appointments

MPH Health Care AG, Annual General Meeting, Jul 09, 2026

New major risk - Revenue and earnings growth

Dermapharm Holding SE, Annual General Meeting, Jun 26, 2026

SynBiotic SE, Annual General Meeting, Apr 23, 2026

Cannovum Cannabis AG, Annual General Meeting, Nov 20, 2025